Clinical Trials Browser

Unknown × OTHER × Neoplasm, Residual × Clear all

NCT06125106 2023-11-09

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Phase 1 Unknown

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05969938 2023-08-01

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Gastrointestinal

Rectal Neoplasms, Neoplasm, Residual

NCT05956977 2023-07-24

Neuro3DUS

Phase NA Unknown

Neoplasm, Residual

NCT05955079 2023-07-21

ctDNA-endo

Endometrial Neoplasms, Neoplasm, Residual

NCT05900583 2023-06-12

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm, Residual

NCT03189576 2023-05-26

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Phase NA Unknown

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT05743959 2023-05-22

ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma, Neoplasm, Residual

NCT05603156 2022-11-02

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Phase NA Unknown

Neoplasm, Residual

NCT05578625 2022-10-13

ctDNA Methylation Sequencing for Myeloma

Multiple Myeloma, Neoplasm, Residual

NCT05536700 2022-09-13

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma, Neoplasm, Residual

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04375683 2022-03-24

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Phase 3 Unknown

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04604691 2022-03-08

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Phase 1 Unknown

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05167604 2021-12-22

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Phase 1/2 Unknown

Adenocarcinoma of Lung, Neoplasm, Residual

NCT01894477 2021-06-03

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2 Unknown

102 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Neoplasm, Residual, Myelodysplastic-Myeloproliferative Diseases

NCT03702088 2019-11-19

Place of the Hevylite Test in the Evaluation of MRD in Myeloma

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT04122092 2019-11-18

EUCADD

Multiple Myeloma, Neoplasm, Residual, Chromosomal Instability

NCT03330769 2019-04-17

UPSTREAM

Arthritis, Psoriatic, Neoplasm, Residual

NCT03662087 2018-09-07

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Phase 2/3 Unknown

Neoplasm, Residual

NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Phase 2/3 Unknown

Neoplasm, Residual

NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Phase NA Unknown

Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

NCT01883219 2017-11-08

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Philadelphia Chromosome, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02400827 2015-03-27

OVAMAR

Neoplasm, Residual

NCT02400970 2015-03-27

TESTIMAR

Neoplasm, Residual

NCT01665001 2012-08-17

Personalized Therapy of Precursor Lymphoid Neoplasms

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00551577 2007-10-31

PRIMOVAR-1

Phase 2 Unknown

Ovarian Neoplasms, Neoplasm, Residual